BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23815917)

  • 1. [Diagnostic value of dysplasia characteristics in typing of myelodysplastic syndrome].
    Li J; Zhang M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):657-61. PubMed ID: 23815917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.
    Mangi MH; Mufti GJ
    Blood; 1992 Jan; 79(1):198-205. PubMed ID: 1370203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia.
    Della Porta MG; Lanza F; Del Vecchio L;
    Cytometry B Clin Cytom; 2011; 80(4):201-11. PubMed ID: 21674774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysplasia features of myelodysplastic syndrome in ethnically Chinese people.
    Xiong B; Tang ZH; Zou P; Yue QF; Chen WX; Liu XY
    Acta Haematol; 2014; 131(2):126-32. PubMed ID: 24158033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of Morphological Examination, Cytochemical Staining Combined with Bone Marrow Biopsy in Differential Diagnosis of Myelodysplastic Syndrome with Low Blasts and Hemolytic Anemia].
    Gu LL; Kang HY; Pan YL; Liu GX; Ge SJ; Li MY; Wang CB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):138-43. PubMed ID: 26913410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic megakaryocyte dysplasia in the myelodysplastic syndromes.
    Hatfill SJ; Fester ED; Steytler JG
    Hematol Pathol; 1992; 6(2):87-93. PubMed ID: 1607344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis on laboratory and clinical characteristics in 65 cases of myelodysplastic syndrome].
    Chen BA; Gao C; Ding J; Ding JH; Sun YY; Zhao G; Cheng J; Wang J; Bao W; Song HH; Xia GH; Ma JL; Wu LL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1472-6. PubMed ID: 20030929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic significance of detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelodysplastic syndrome.
    Kuriyama K; Tomonaga M; Matsuo T; Ginnai I; Ichimaru M
    Br J Haematol; 1986 Aug; 63(4):665-9. PubMed ID: 3460627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Classification and clinical findings of myelodysplastic syndromes].
    Tsuruda K; Hasegawa H; Fuchigami M; Uno N; Morinaga Y; Miyazaki Y; Yanagihara K
    Rinsho Byori; 2014 Apr; 62(4):359-68. PubMed ID: 25022065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS-related bone marrow lesions--myelodysplastic features or predominant inflammatory-reactive changes (HIV-myelopathy)? A comparative morphometric study by immunohistochemistry with special emphasis on apoptosis and PCNA-labeling.
    Thiele J; Zirbes TK; Bertsch HP; Titius BR; Lorenzen J; Fischer R
    Anal Cell Pathol; 1996 Aug; 11(3):141-57. PubMed ID: 8888951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
    Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.
    Senent L; Arenillas L; Luño E; Ruiz JC; Sanz G; Florensa L
    Haematologica; 2013 Apr; 98(4):568-75. PubMed ID: 23065505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens.
    Thiele J; Quitmann H; Wagner S; Fischer R
    J Clin Pathol; 1991 Apr; 44(4):300-5. PubMed ID: 2030148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease.
    Stevens EC; Rosenthal NS
    Am J Clin Pathol; 2001 Aug; 116(2):177-82. PubMed ID: 11488063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone marrow histological changes in myelodysplastic syndrome and its clinical significance].
    Liu XF; Wang BM; Yi FH
    Zhonghua Nei Ke Za Zhi; 1991 Nov; 30(11):675-7, 729. PubMed ID: 1815870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance.
    Zhang X; Sokol L; Bennett JM; Moscinski LC; List A; Zhang L
    Leuk Res; 2016 Apr; 43():18-23. PubMed ID: 26927701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic significance of morbidly hematopoietic characteristics in 69 patients with myelodysplastic syndrome].
    Wu YN; Luo ZB; Wang C; Li J; Luo HY; He DY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):150-4. PubMed ID: 25687064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.